TP53 and carcinoma: Thus, to validate the effect of SC in the TP53 network, we considered the urogenital system in the TCGA database, including bladder urothelial (N = 406) and uterine corpus endometrial (N = 545) carcinomas, which are commonly treated with paclitaxel chemotherapy [22].